Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib

Fig. 2

Simulations of the effects of axitinib supplementation in a standard TKI treatment. The standard TKI is taken at t=0 for imatinib, dasatinib and bosutinib, and at t=0 and t=12 for nilotinib. Axitinib administration is at t=0 when taken with nilotinib and at the time (t=22h) indicated by the vertical dotted lines when taken with each of the other drugs. Administration time for axitinib has been optimised to achieve the minimum instantaneous χ

Back to article page